Form 4: Mangoceuticals CFO Acquires 25,000 Shares, Disposes of 38,334 Shares

Mangoceuticals' Chief Financial Officer, Eugene M. Johnston, acquired 25,000 shares and disposed of 38,334 shares of common stock on November 11, 2024.

Summary

• Eugene M. Johnston, the Chief Financial Officer of Mangoceuticals, Inc., reported a transaction involving the company's common stock.
• On November 11, 2024, Mr. Johnston acquired 25,000 shares of common stock at a price of $0.
• These shares were issued as compensation for his role as Chief Financial Officer under the company's 2022 Equity Incentive Plan.
• On the same day, Mr. Johnston also disposed of 38,334 shares of common stock.
• The transaction was reported on November 12, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports a routine transaction. The acquisition of shares is positive, but the disposal of a larger number of shares is a potential negative. The overall impact is likely to be minimal.

Positives

• The acquisition of shares by the CFO indicates alignment with the company's interests.

Negatives

• The disposal of 38,334 shares by the CFO could be seen as a negative signal.

Risks

• The disposal of a significant number of shares by a key executive could raise concerns among investors.
• The market may interpret the CFO's actions as a lack of confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders trade company stock. It is a routine disclosure required by the SEC to ensure transparency in insider trading activities.

Comparison to Industry Standards

• The filing is consistent with standard practices for publicly traded companies, where officers and directors are required to disclose their transactions in company stock.
• Similar filings are made by executives at companies like Pfizer, Moderna, and other publicly traded companies when they buy or sell shares.

Stakeholder Impact

• The stock transactions by the CFO may influence investor sentiment.

Key Dates

Keywords

Mangoceuticals, MGRX, CFO, Eugene M. Johnston, stock acquisition, stock disposal, equity incentive plan, insider trading, SEC Form 4